Target identification in solid tumors can help enable therapeutic development against indications of high unmet need and across a wide patient population. Checkpoint therapy has shown that CD8+ T cells are responsible for driving patient responses, and yet the specificities of these T cells cannot be directly determined in an unbiased manner. We have developed a high-throughput platform to directly determine the specificities of clonally enriched and shared patient T cell responses. This information can be used to link clinical responses, immune biomarkers, and T cell specificities to evaluate the most promising shared targets in solid tumors and understand the mechanism of action of current anticancer drugs. These targets can be used to develop T cell therapies or other therapeutic modalities that can be used to improve the outcomes of clinical treatment in an array of solid tumor indications.

Register today using code GENSCRIPT for 10% off your conference pass